tetano
Editor, Senior Moderator
Cell Rep
. 2023 Jan 9;42(1):111998.
doi: 10.1016/j.celrep.2023.111998. Online ahead of print.
Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
Alexandra Tauzin[SUP] 1 [/SUP], Alexandre Nicolas[SUP] 1 [/SUP], Shilei Ding[SUP] 2 [/SUP], Mehdi Benlarbi[SUP] 1 [/SUP], Halima Medjahed[SUP] 2 [/SUP], Debashree Chatterjee[SUP] 2 [/SUP], Katrina Dionne[SUP] 1 [/SUP], Shang Yu Gong[SUP] 3 [/SUP], Gabrielle Gendron-Lepage[SUP] 2 [/SUP], Yuxia Bo[SUP] 4 [/SUP], Josée Perreault[SUP] 5 [/SUP], Guillaume Goyette[SUP] 2 [/SUP], Laurie Gokool[SUP] 2 [/SUP], Pascale Arlotto[SUP] 2 [/SUP], Chantal Morrisseau[SUP] 2 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Valérie Martel-Laferrière[SUP] 1 [/SUP], Gaston De Serres[SUP] 6 [/SUP], Inès Levade[SUP] 7 [/SUP], Daniel E Kaufmann[SUP] 8 [/SUP], Marceline Côté[SUP] 4 [/SUP], Renée Bazin[SUP] 5 [/SUP], Andrés Finzi[SUP] 9 [/SUP]
Affiliations
Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants.
Keywords: B cell responses; COVID-19; CP: Immunology; Omicron subvariants; SARS-CoV-2; coronavirus; humoral responses; hybrid immunity; neutralization; spike glycoproteins; third mRNA vaccine dose.
. 2023 Jan 9;42(1):111998.
doi: 10.1016/j.celrep.2023.111998. Online ahead of print.
Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
Alexandra Tauzin[SUP] 1 [/SUP], Alexandre Nicolas[SUP] 1 [/SUP], Shilei Ding[SUP] 2 [/SUP], Mehdi Benlarbi[SUP] 1 [/SUP], Halima Medjahed[SUP] 2 [/SUP], Debashree Chatterjee[SUP] 2 [/SUP], Katrina Dionne[SUP] 1 [/SUP], Shang Yu Gong[SUP] 3 [/SUP], Gabrielle Gendron-Lepage[SUP] 2 [/SUP], Yuxia Bo[SUP] 4 [/SUP], Josée Perreault[SUP] 5 [/SUP], Guillaume Goyette[SUP] 2 [/SUP], Laurie Gokool[SUP] 2 [/SUP], Pascale Arlotto[SUP] 2 [/SUP], Chantal Morrisseau[SUP] 2 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Valérie Martel-Laferrière[SUP] 1 [/SUP], Gaston De Serres[SUP] 6 [/SUP], Inès Levade[SUP] 7 [/SUP], Daniel E Kaufmann[SUP] 8 [/SUP], Marceline Côté[SUP] 4 [/SUP], Renée Bazin[SUP] 5 [/SUP], Andrés Finzi[SUP] 9 [/SUP]
Affiliations
- PMID: 36656710
- DOI: 10.1016/j.celrep.2023.111998
Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants.
Keywords: B cell responses; COVID-19; CP: Immunology; Omicron subvariants; SARS-CoV-2; coronavirus; humoral responses; hybrid immunity; neutralization; spike glycoproteins; third mRNA vaccine dose.